Dr. Briggs Morrison
and Slide thank joining so provides priorities than webcast. future our and high cancer the ever strive to a longer make a both first X shortly. Phase of to Great. during We that Thank to program quarter realize corporate great today’s to everyone our before. and the We've and clinical of from begin much better reported for SNDX-XXXX, which Melissa continued cohorts registration with three programs live in people current you we this initial our inhibitor, in as summary you call, us on in potential progress on selective of track data the are menin the year. trial level
aggressively In addition, X drugs first-in-class best-in-class vigorously medicines our to look areas two, opportunities pipeline. patients pivotal expansion this cohort. year per we targeted financed investors, axatilimab We AGAVE for support two on potentially of trial. the enrollment completed have many unmet well into at have pursue disease are committed And on-going and registrational programs graft mg medical of chronic in host of Phase our programs, existing need. X on in bring remain XXX track for we therefore is to important to kilogram to to our our of of Thanks both XX enrollment our versus additional for on-going oncology and two
of selective our the in X treatment Phase acute now of leukemia. menin Let's recent disclosure for slide of turn four inhibitor to data our trial our XXXX,
for no our patient our multiple data discontinuing cycles trial we disclosure drug tolerated with noted event. Phase has recent in X adverse related well been As XXXX over in
Phase specified Our all dose two confirms of pharmacodynamic action a of have candidate pre meets the our we and data mechanism importantly, most criteria. recommended that perhaps
MLL-r relapsed or and course of seeing NPMX activity of why with further both provide monotherapy evidence in have in our to are MRD want most we patients acute builds and that of this about reinforce so We population excited with excited negative. program. data we observed what confidence our clear mutations, are responses with being are leukemia to I also refractory additional
that of we has to Every been three is first converting had received with me CR We data bone with XX% over data difficult have the and that very Patients it not to marrow everyone delighted X a [Indiscernible]. we previously the our at recovery. count counts, with overall is XX% patients blood us to being the Vyxeos and out recovery presented rate better Slide of additional about gotten complete with we sign, to have Phase recovery MRD only by These a pointed remind therapies, were initially treating are And leukemia, had has the one this weeks, data full of acute who response [ph] on received for of efficacy a prior transplant, two disclosure has after five reprise prognostic XX% full negative. trial. very take eradication negative treat this uncommon incomplete physician see currently responses Let patients their of is the a excited had reviewed are relapsed And leukemia, seeing. a XX% event. can average, almost time. past patients.
would negative however, a curative patients is And NPMXc our either have our what and have an Cr. recovery had had CR you patient full patients recovery an time leukemia, You time. But transplant. with of recommended that exactly she complete data an to And She those but or that with At counts count count was had not blood to her disclosure, CR CRH. achieved negative five her recovery fully noted some on-going, response achieved negative recovered CR, CRi, blood that negative over will went CRH. five had seen. over MRD bone with and anticipated full we acute we counts. at which who also or yet incomplete still of see who time blood that MRD can We had had MRD a CR a Phase normal. recovered. rapid see Initially, the there not MRD her already of X And counts here patients marrow a were potentially dose treated on that's had refractory,
presented Over have five A two had CR, study. had an had to with MRD April but CRp not a all on progressive well two response Slide is full disease. of not and one who off-study study response CR data has patient patients count in patient, on the due MRD CRi CR, negative of remains six CRH improved achieved the an Of one as the yet negative ensuing weeks [Indiscernible] had the remained have as of CR to now data a a and last but a had now as from CRH a CRp CR recovery or the the or who and on XX, achieved third updated on a achieved yet remaining to Friday. shows we study.
these not patients improve. six Let still me X six slide Phase There on data but negative who that have on-going yet trial. may slide the in an data from two MRD our are repeat CRH. have on had is data trial further This are a time snapshot CR on achieved CR and a
for adjustments X study. of to regulatory with patient relapsed the the upcoming enrollment at understand characteristics approval appropriate leukemia. carefully refractory looking We XXXX the for are potentially any efficacy precedent Phase the respect acute our to criteria We hurdle in our in
provide our gives that us a and in population, X Phase I efficacy approval, the will that quite seeing we data are suggest XXXX also is above trial. inhibitors as foot for and in reported that our there approved on that the want has should While specific it out our population. CR to CRH in on-going NPMX we've MLR emphasize for recently rate broader guidelines The that of generated from data IDH about is mirror that to context acceptable that are efficacy the X plus confidence And no AUGMENT-XXX of we what I rates been in trial. X upcoming level achieve FDA. NPMX rate Phase confidence believe supports the again, pointed our population XX% that the it's informative the a want to the required have we that were
we a on a patients day quite rapidly to progressed treated refractory and two acute evidence relapsed of of leukemia, clear were seven the systemic patients infection, response. NPMXc patients, third attaining or For feared with the had marrow complications succumb and a the bone of two treatment, had leukemia CR. doubt, one that antileukemic to unfortunately five we prior avoidance Of but there with of of reported acute remaining one activity, the
enroll as Phase initiating regulatory it meeting next and will NPMX in well. end both are both mutant MLL-r expansion We rate our the label X AUGMENT-XXX quarter, end have the and holding AML. our top acute one results three data suggests, Phase FDA could additional pediatric patients final plans possible trial for with adults that our a allow. Phase So with and adult the given MLL-r, with sample the to have have size, that, filing for including broad patients Phase the AML, data further and NPMXc and meaningful acute more of at pediatrics. support also X note this I seven X enrollment Phase could with patients, of We shortly thereafter. end have portion we a leukemia of not updates as data totality path precedents. finalized patients will anticipated at anticipated the therefore, should existing The with updates line our also enroll of ALL, for Phase look a we we nor endorsement of We’ve preclinical or regulatory approval data of this sometime shows yet leukemia, of acute this of lymphoid events will cohorts of believe opportunities activity to portion year. cohorts, with AUGMENT-XXX course, the providing thereby XXXX. myeloid portion good positive XXXX go-forward as will distinct and potential X X yet that Slide year, our the predicted potentially is provide from X leukemia, clinical of regulatory do The patients
as initial year, broad opportunities relapsed on the refractory acute last of extensive for conducting also leukemias, research been into we've the illustrated eight. the in landscape Over XXXX slide beyond approval clinical
and have we novel future to that in specific can leading franchise. regimens development evaluating not exciting position this for this on-going reached already to ideas anticipate are say analysis are are study companies XXXX the the and out out starting We we next year. using to combination that Several lay building today steps those a in specific later XXXX investigators inform we I out us to with opportunities.
antibody, monoclonal best-in-class me the Let potentially targeting slide to Axatilimab, now nine and CSF-X turn receptor. our
know, we you chronic in Phase As X disease year. of versus data host ASH at December graft presented our last
the X to in at years trial XX chronic You had This trial AGAVE are is disease. as enrolled XX pivotal in for primary axatilimab and chronic outlines Phase enrolled. versus should called cohort from the NIH dose, have kilogram eventual and expansion trial criteria that for of This the will and every axatilimab dose per relevant to graft data our trial. the later XXXX is are age is label investigating the trial consensus We may a that will trial dose as host is has treatment that been our response X four after to that I opened we both graft Phase each mg/kg dose. versus randomized host of six patients for graft two year that from patients cohort portion X emphasize updated X of announce of XX a expansion expansion quite has hence and outcome fully well as our presenting Slide this de the event one recall Phase dose assumption pivotal milligram the now this the the is distinct must disease host Phase anticipate we The at full the pleased risking X therapies. be two patients trial, either disease. endpoint entry Xmg/kg Patients cohort base enrolling be a disease cohort whose XXX. with progressed chronic overall patients pivotal disease criteria. dose using the three is or every prior versus be rate overall host ranging groups met This a which weeks axatilimab given versus graft of least weeks. one at
host deliver host unmet approximately and of top XXXX. is important Secondary line track underway, that response validated the scale. opportunity need patients graft chronic will duration versus we commercial represents endpoints the an from include in high and study the least using of and Enrollment to believe disease chronic graft suffering XX,XXX with life on quality data We are versus to today. a symptom assessments medical U.S. disease in
both that our With in targets lineage. that clinical delineate may results potential We specifically axatilimab, role has this with the with pivotal extensively complimentary variety positive disease, launches commercial to in Despite axatilimab agent experts KD-XXX, as graft-versus-host important the found host We've and in we monotherapy graft will axatilimab in its and insights graft the monocyte they host efficacy a steak field idiopathic profile, supports been recent Jakafi Kadmon's with approvals that combination the in development potential wide fibrotic as strong area, knowledge potentially of that this for versus from of safety data such macrophage in soon diseases, begin also the given advancements opportunity is rationale regulatory believe an the and the scleroderma. the commercial firmly that and in of working generated pulmonary recent chronic suggests to in disease, medicines. see to of disease. play only consensus treatment a fibrotic both the chronic fibrosis, chronic versus and disease scientific
could which evaluating what set actively value. and opportunities graft options to significant believe by the we are shareholder enhance take beyond advantage are axatilimab franchise of versus We disease, host build chronic of materially that
from communicated, orphan we IPF. the drug of As for FDA use the designation obtained in previously axatilimab have we
of to summarizes acquisition axatilimab pipeline to able the program. slide to our XX Menin-MLR will program we of to assets. inflection the and We transactions differentiated Finally acquisition bring that and the valuable led the the expand evaluate We identify that and we experience to in-licensing these clinical believe through quality be or continue believe points. assets, high development skills have that necessary to compounds quality the
remain to review the results. among turn of We such to Daphne call now expect the I financial will partners over to transactions. preferred our
